Table 5. Histology type-specific cause-specific survival based on lymphadenectomy performance.
| Histology type | Nodal extent | GOG criteria | CGR criteria | Mayo criteria | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 10-yr (%) | HR (95% CI) | p-value | 10-yr (%) | HR (95% CI) | p-value | 10-yr (%) | HR (95% CI) | p-value | ||
| Serous | Inadequate | 68.5 | 1.00 | 71.4 | 1.00 | 73.5 | 1.00 | |||
| Adequate | 76.4 | 0.67 (0.58–0.78) | <0.001 | 76.5 | 0.73 (0.63–0.85) | <0.001 | 73.9 | 0.86 (0.70–1.06) | 0.17 | |
| Unstaged | 56.5 | 1.69 (1.50–1.90) | <0.001 | 56.5 | 1.86 (1.67–2.07) | <0.001 | 56.5 | 2.06 (1.87–2.27) | <0.001 | |
| Endometrioid | Inadequate | 75.3 | 1.00 | 76.4 | 1.00 | 79.6 | 1.00 | |||
| Adequate | 83.2 | 0.61 (0.49–0.76) | <0.001 | 84.9 | 0.59 (0.47–0.73) | <0.001 | 84.2 | 0.76 (0.56–1.02) | 0.07 | |
| Unstaged | 72.5 | 1.11 (0.90–1.38) | 0.33 | 72.5 | 1.19 (0.98–1.45) | 0.08 | 72.5 | 1.43 (1.19–1.71) | <0.001 | |
| Clear cell | Inadequate | 85.6 | 1.00 | 85.8 | 1.00 | 86.8 | 1.00 | |||
| Adequate | 88.5 | 0.73 (0.60–0.88) | 0.001 | 89.3 | 0.71 (0.58–0.86) | <0.001 | 90.5 | 0.66 (0.50–0.88) | 0.004 | |
| Unstaged | 79.8 | 1.45 (1.22–1.74) | <0.001 | 79.8 | 1.52 (1.29–1.78) | <0.001 | 79.8 | 1.65 (1.43–1.91) | <0.001 | |
| Mucinous | Inadequate | 88.6 | 1.00 | 88.6 | 1.00 | 89.8 | 1.00 | |||
| Adequate | 88.7 | 0.91 (0.69–1.20) | 0.51 | 88.8 | 0.90 (0.68–1.19) | 0.46 | 83.6 | 0.80 (0.53–1.22) | 0.31 | |
| Unstaged | 82.5 | 1.54 (1.21–1.96) | 0.001 | 82.5 | 1.56 (1.26–1.93) | <0.001 | 82.5 | 1.58 (1.30–1.91) | <0.001 | |
Unadjusted Cox proportional hazard regression test for p-values. Significant p-values are emboldened.
CGR, Collaborative Group Report criteria for bladder cancer; CI, confidence interval; GOG, Gynecologic Oncology Group; HR, hazard ratio; 10-yr (%), 10-year cause-specific survival rate.